A Phase 1, First-in-Human, Dose Escalation Study of JNJ-63898081, in Subjects With Advanced Stage Solid Tumors
Latest Information Update: 31 Mar 2022
At a glance
- Drugs JNJ 63898081 (Primary) ; JNJ 63898081 (Primary)
- Indications Adenocarcinoma; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
Most Recent Events
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 02 Dec 2021 Status changed from active, no longer recruiting to completed.
- 15 Jul 2021 Status changed from recruiting to active, no longer recruiting.